TD Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

TD Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-636	Closed	-$402K	–	1392
2015 Q2	$402K	Hold	636	–	–	﹤0.01%	1179
2015 Q1	$327K	Hold	636	–	–	﹤0.01%	1221
2014 Q4	$341K	Hold	636	–	–	﹤0.01%	1194
2014 Q3	$954K	Buy	636 +123	+24%	+$178K	﹤0.01%	909
2014 Q2	$703K	Hold	513	–	–	﹤0.01%	959
2014 Q1	$713K	Buy	513 +47	+10%	+$54.6K	﹤0.01%	954
2013 Q4	$464K	Hold	466	–	–	﹤0.01%	1035
2013 Q3	$486K	Buy	466 +206	+79%	+$220K	﹤0.01%	984
2013 Q2	$284K	Buy	+260	New	+$290K	﹤0.01%	1053

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TD Asset Management's VIRX Position: Q3 2015 in Review

TD Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 636 shares — an estimated $402K sold.

TD Asset Management first reported a position in VIRX in Q2 2013 and held it in 9 quarters. The position peaked at $954K in Q3 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

TD Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
TD Asset Management sold 636 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $402K.
TD Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
TD Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $954K in Q3 2014.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on TD Asset Management's 13F filing for Q3 2015, filed 12 Nov 2015.